Blog

0 17

Patent Number: 9,250,243

Grant date: December 31, 1969
Priority date: September 21, 2006
Estimated expiration date: September 21, 2026
Inventor(s): Singh; Sharat (Los Altos Hills, CA), Harvey; Jeanne (Livermore, CA)
Assignee(s): NESTEC S.A. (Vevey, CH)
External link: USPTO website

Abstract:

The present invention provides compositions and methods for detecting the activation states of components of signal transduction pathways in tumor cells. Information on the activation states of components of signal transduction pathways derived from use of the invention can be used for cancer diagnosis, prognosis, and in the design of cancer treatments.

0 21

Patent Number: 9,250,231

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Pinset; Christian (Paris, FR)
Assignee(s): Centre D’Etude Des Cellules Souches (Evry, FR)
External link: USPTO website

Abstract:

The invention provides a method for selecting pharmaceutical compounds that enhance inhibition of mevalonate synthesis in which mesodermal stem cells (MSC type) that are derived from human pluripotent cells or from induced stem cell are contacted with pharmaceutical compounds to be tested in the presence of an inhibitor of mevalonate synthesis. Pharmaceutical compounds are then identified which enhance cell toxicity in the presence of the inhibitors.

0 15

Patent Number: 9,250,230

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Liu; Shi V. (Apex, NC)
Assignee(s):
External link: USPTO website

Abstract:

The invention uses induced pluripotent stem cells (iPSCs) for screening anti-neoplastic agents by examining the capability of a single agent, compound or drug, or a combination of multiple agents, compounds or drugs, for inhibiting or suppressing one or more neoplastic activities or processes, including aerobic glycolysis and neoplastic anabolism and, thus, inhibiting rapid growth and excessive reproduction of neoplastic cells. Agents, compounds or drugs may also be screened for their potential in inhibiting an invasion and/or migration of neoplastic cells into healthy or normal tissues and/or cells and a metastasis of neoplastic cells into other sites of the body. Anti-neoplastic agents, compounds and/or drugs found through these methods may represent broad-spectrum anti-neoplastic agents, compounds and/or drugs that preferentially target and damage neoplastic tumor or cancer cells but exert limited or minimal harm to normal or healthy cells.

0 18

Patent Number: 9,249,459

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Hamilton; Amy (San Francisco, CA), Lin; Min (Foster City, CA), Mir; Alain (Cupertino, CA), Pieprzyk; Martin (Belmont, CA)
Assignee(s): Fluidigm Corporation (South San Francisco, CA)
External link: USPTO website

Abstract:

The present invention provides methods for analysis of genomic DNA and/or RNA from small samples or even single cells. Methods for analyzing genomic DNA can entail whole genome amplification (WGA), followed by preamplification and amplification of selected target nucleic acids. Methods for analyzing RNA can entail reverse transcription of the desired RNA, followed by preamplification and amplification of selected target nucleic acids.

0 17

Patent Number: 9,249,426

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Girard-Gagnepain; Anais (Lyons, FR), Verhoeyen; Els (Lyons, FR), Lavillette; Dimitri (Lyons, FR), Cosset; Francois-Loic (Lyons, FR)
Assignee(s): Institut National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR) Ecole Normale Superieur de Lyon (Lyons, FR)
External link: USPTO website

Abstract:

The present invention concerns a pseudotyped viral vector particle for transferring biological material into cells, wherein said vector particle comprises at least:–a chimeric envelope glycoprotein which comprises or consists in a fusion of the transmembrane and extracellular domain of a baboon endogenous retrovirus (BaEV) envelope glycoprotein and the cytoplasmic tail domain of a murine leukemia virus (MLV) envelope glycoprotein; or–a modified BaEV envelope glycoprotein wherein the cytoplasmic tail domain is devoid of the fusion inhibitory R peptide.

0 16

Patent Number: 9,249,412

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Zacouto; Fred (Paris, FR)
Assignee(s):
External link: USPTO website

Abstract:

A method of partial, rapid and direct genetic and epigenetic reprogramming of biological cells without returning to the embryonic state can partially reprogram a cell to be treated to specifically modify the biological age of said cell to be treated without causing functional de-differentiation of said cell to be treated, said cell to be treated always remaining as a specialized functional cell that is immunologically autologous to the donor tissue from which said cell to be treated is derived, and for which the phenotype is preserved and/or rejuvenated.

0 17

Patent Number: 9,249,394

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Hijikata; Makoto (Kyoto, JP), Aly; Hassan Hussein (Kyoto, JP), Yamaguchi; Tatsuya (Tsuruga, JP)
Assignee(s): KYOTO UNIVERSITY (Kyoto-shi, JP) TOYOBO CO., LTD. (Osaka-shi, JP)
External link: USPTO website

Abstract:

An object of this invention is to provide a method, etc., for efficiently proliferating a pluripotent epithelial somatic stem cell. A method for producing an epithelial somatic stem cell comprising Steps (A) and (B) below: (A) expressing a gene of a protein having an activity for causing a cell in G0 phase or G1 phase to enter S phase, in a cell population including an epithelial somatic stem cell; and (B) culturing the cell obtained in Step (A) in the presence of an extracellular growth factor.

0 14

Patent Number: 9,249,393

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Gimble; Jeffery M. (Baton Rouge, LA), Ludlow; John W. (Carrboro, NC)
Assignee(s): BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (Baton Rouge, LA) ARTECEL, INC (Sunnyvale, CA)
External link: USPTO website

Abstract:

The present invention provides a method to derive hepatic stem cells from stem cells derived from non-liver tissue. In one embodiment of the invention, hepatic stem cells are derived from adipose stem cells. The invention also provides a method of enhancing hepatic cytokine production (e.g., HGF) from ASCs, which may be useful in the regeneration of liver tissue when transplanted in vivo. Tissue culture conditions, including media conditions, are provided.

0 15

Patent Number: 9,249,392

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Marban; Eduardo (Beverly Hills, CA), Li; Tao-Sheng (Nanchang, CN)
Assignee(s): Cedars-Sinai Medical Center (Los Angeles, CA)
External link: USPTO website

Abstract:

The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies.

0 16

Patent Number: 9,249,391

Grant date: December 31, 1969
Priority date: October 28, 1999
Estimated expiration date: October 28, 2019
Inventor(s): Huang; Yadong (San Francisco, CA), Ring; Karen (San Francisco, CA)
Assignee(s): The J. David Gladstone Institutes (San Francisco, CA)
External link: USPTO website

Abstract:

The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.